Fusobacterium and Escherichia: models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening

References

• Dove WF, Clipson L, Gould KA, et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 1997;57(5):812-14
   PubMed Web of Science ®Google Scholar
• Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 2013;66(2):462-70
   PubMed Web of Science ®Google Scholar
• Zhu Q, Jin Z, Wu W, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One 2014;9(6):e90849
   Google Scholar
• Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22(2):292-8
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22(2):299-306
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115(2):281-6
   PubMed Web of Science ®Google Scholar
• Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology 2004;127(1):80-93
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29(7):2727-37
   PubMed Web of Science ®Google Scholar
• Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol 2002;97(4):939-46
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002;17(8):849-53
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14(2):207-15
   PubMed Web of Science ®Google Scholar
• DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246(1):379-400
   PubMed Web of Science ®Google Scholar
• Lozyns’ka MR, Plavski A, Lozyns’kyi Iu S. [Clinical and genetic features of APC- and MYH-mutation-negative patients with multiple polyposis of large bowel that tested by conventional methods]. Tsitol Genet 2014;48(1):18-24
   PubMedGoogle Scholar
• Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14(2):195-206
   PubMed Web of Science ®Google Scholar
• Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int 2012;62(6):368-80
   PubMed Web of Science ®Google Scholar
• Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014;74(5):1311-18
   PubMed Web of Science ®Google Scholar
• Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 2014;20(4):859-67
   PubMed Web of Science ®Google Scholar
• Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2007;13(10):1277-83
   PubMed Web of Science ®Google Scholar
• Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338(6103):120-3
   PubMed Web of Science ®Google Scholar
• Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15(1):59-67
   PubMed Web of Science ®Google Scholar
• Cougnoux A, Dalmasso G, Martinez R, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 2014;63(12):1932-42
   PubMed Web of Science ®Google Scholar
• Nesic D, Hsu Y, Stebbins CE. Assembly and function of a bacterial genotoxin. Nature 2004;429(6990):429-33
   PubMed Web of Science ®Google Scholar
• Tyrer PC, Frizelle FA, Keenan JI. Escherichia coli-derived outer membrane vesicles are genotoxic to human enterocyte-like cells. Infect Agent Cancer 2014;9(1):2
   PubMed Web of Science ®Google Scholar
• Khan AA. In silico prediction of Escherichia coli proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. J Comput Biol 2014;21(6):466-75
   PubMed Web of Science ®Google Scholar
• Martin P, Marcq I, Magistro G, et al. Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli. PLoS Pathog 2013;9(7):e1003437
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47(2):241-59
   PubMed Web of Science ®Google Scholar
• Reddy BS, Narasawa T, Weisburger JH, Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J Natl Cancer Inst 1976;56(2):441-2
   PubMedGoogle Scholar
• Zhu Y, Hua P, Rafiq S, et al. Ca2+- and PKC-dependent stimulation of PGE2 synthesis by deoxycholic acid in human colonic fibroblasts. Am J Physiol Gastrointest Liver Physiol 2002;283(3):G503-10
   Google Scholar
• Gupta S, Natarajan R, Payne SG, et al. Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J Biol Chem 2004;279(7):5821-8
   PubMed Web of Science ®Google Scholar
• Rao YP, Studer EJ, Stravitz RT, et al. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 2002;35(2):307-14
   PubMed Web of Science ®Google Scholar
• Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell 2004;15(5):2156-63
   PubMed Web of Science ®Google Scholar
• Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3(4):243-52
   PubMed Web of Science ®Google Scholar
• Prevention CDC. Colorectal cancer tests save lives: office of the associate director for communications (OADC). 2013. Available from: www.cdc.gov/vitalsigns/colorectalcancerscreening/ [cited 2014]
   Google Scholar
• Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005;142(2):81-5
   PubMed Web of Science ®Google Scholar
• Feinman M, Haut ER. Lower gastrointestinal bleeding. Surg Clin North Am 2014;94(1):55-63
   PubMed Web of Science ®Google Scholar
• Yeasmin F, Ali MA, Rahman MA, et al. A comparative study of chemical and immunological method of fecal occult blood test in the diagnosis of occult lower gastrointestinal bleeding. Bangladesh Med Res Counc Bull 2013;39(2):52-6
   PubMedGoogle Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287-97
   PubMed Web of Science ®Google Scholar
• Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012;61(5):739-45
   PubMed Web of Science ®Google Scholar
• Wu CW, Ng SC, Dong Y, et al. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res 2014;20(11):2994-3002
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127(1):118-26
   PubMed Web of Science ®Google Scholar
• Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012;7(9):e44398
   PubMed Web of Science ®Google Scholar
• Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011;6(1):e16393
   PubMed Web of Science ®Google Scholar
• Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9(4):279-90
   PubMed Web of Science ®Google Scholar
• Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014;33(8):1381-90
   PubMed Web of Science ®Google Scholar
• Warren RL, Freeman DJ, Pleasance S, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013;1(1):16
   PubMed Web of Science ®Google Scholar
• Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing 2013;10(1):31
   PubMed Web of Science ®Google Scholar